Uncommon histiocytic disorders: The non-Langerhans cell histiocytoses

被引:180
|
作者
Weitzman, S
Jaffe, R
机构
[1] Hosp Sick Children, Div Hematol Oncol, Dept Pediat, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Dept Pediat, Div Hematol Oncol, Toronto, ON, Canada
[3] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[4] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA
关键词
histiocytic disorders; Langerhans cell histiocytosis; non-Langerhans cell; histiocytosis;
D O I
10.1002/pbc.20246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Histiocytic disorders are currently identified by their component cells. The non-Langerhans Cell Histiocytoses (non-LCH) are a group of disorders defined by the accumulation of histiocytes that do not meet the phenotypic criteria for the diagnosis of Langerhans cells (LCs). The non-LCH consist of a long list of diverse disorders which have been difficult to categorize. A conceptual way to think of these disorders that make them less confusing and easier to remember is proposed based on immunophenotyping and clinical presentation. Results. Clinically the non-LCH can be divided into 3 groups, those that predominantly affect skin, those that affect skin but have a major systemic component, and those that primarily involve extracutaneous sites, although skin may be involved. Immunolhistochernically many of the non-LCH appear to arise from the same precursor cell namely the dermal dendrocyte. Juvenile Xanthogranuloma (JXG) is the model of the dermal dendrocyte-derived non-LCH. Other non-LCH with differing clinical presentation and occurring at different ages but with an identical immunophenotype appear to form a spectrum of the same disorder, deriving from the same precursor cell at different stages of maturation. They should be considered as members of a JXG family. Non-JXG family members include Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Conclusion. The non-LCH can be classified as JXC family and non-JXG family and subdivided according to fairly clear-cut clinical criteria. Utilization of this type of approach will allow better categorization, easier review of the literature and more accurate therapy decision-making.
引用
收藏
页码:256 / 264
页数:9
相关论文
共 43 条
  • [41] Complete remission of nodular pulmonary Langerhans cell histiocytosis lesions induced by 2-chlorodeoxyadenosine in a non-smoker
    Aerni, Michelle R.
    Aubry, Marie Christine
    Myers, Jeffery L.
    Vassallo, Robert
    RESPIRATORY MEDICINE, 2008, 102 (02) : 316 - 319
  • [42] Brief report - Non-identical twin sisters concordant for Langerhans cell histiocytosis and discordant for secondary acute promyelocytic leukemia
    Dufour, C
    Lanciotti, M
    Micalizzi, C
    Valetto, A
    Haupt, R
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 37 (01): : 70 - 72
  • [43] Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders
    Papo, Matthias
    Cohen-Aubart, Fleur
    Trefond, Ludovic
    Bauvois, Adeline
    Amoura, Zahir
    Emile, Jean-Francois
    Haroche, Julien
    CURRENT ONCOLOGY REPORTS, 2019, 21 (07)